Qube Research & Technologies (QRT)
AKBA icon

Qube Research & Technologies (QRT)’s Akebia Therapeutics AKBA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33M Sell
2,395,215
-595,552
-20% -$818K ﹤0.01% 1880
2025
Q4 		$4.82M Sell
2,990,767
-215,417
-7% -$451K ﹤0.01% 1792
2025
Q3 		$8.75M Buy
3,206,184
+1,491,640
+87% +$4.96M 0.01% 1410
2025
Q2 		$6.24M Buy
1,714,544
+646,267
+60% +$1.78M 0.01% 1573
2025
Q1 		$2.05M Sell
1,068,277
-123,082
-10% -$251K ﹤0.01% 1947
2024
Q4 		$2.26M Sell
1,191,359
-132,370
-10% -$230K ﹤0.01% 1832
2024
Q3 		$1.75M Sell
1,323,729
-420,887
-24% -$562K ﹤0.01% 1807
2024
Q2 		$1.78M Sell
1,744,616
-518,060
-23% -$640K ﹤0.01% 1687
2024
Q1 		$4.14M Buy
2,262,676
+2,005,503
+780% +$3.21M 0.01% 1349
2023
Q4 		$319K Buy
257,173
+135,757
+112% +$138K ﹤0.01% 2548
2023
Q3 		$138K Sell
121,416
-314,853
-72% -$404K ﹤0.01% 2548
2023
Q2 		$399K Buy
+436,269
New +$421K ﹤0.01% 1576
2023
Q1 		– Sell
-14,855
Closed -$8.57K – 2500
2022
Q4 		$8.57K Sell
14,855
-194,900
-93% -$61.1K ﹤0.01% 2287
2022
Q3 		$66K Sell
209,755
-388,624
-65% -$152K ﹤0.01% 2076
2022
Q2 		$211K Buy
+598,379
New +$251K ﹤0.01% 1716
2021
Q3 		– Sell
-41,564
Closed -$158K – 2148
2021
Q2 		$158K Buy
+41,564
New +$140K ﹤0.01% 1850
2020
Q3 		– Sell
-21,616
Closed -$294K – 1639
2020
Q2 		$294K Buy
+21,616
New +$224K ﹤0.01% 1307

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AKBA Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Akebia Therapeutics (AKBA) stake by 20% in Q1 2026, selling an estimated $818K and leaving 2,395,215 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

Qube Research & Technologies (QRT) first reported a position in AKBA in Q2 2020 and has held it in 17 quarters since. The position peaked at $8.75M in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Qube Research & Technologies (QRT) held 2,395,215 shares of Akebia Therapeutics worth $3.33M as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 595,552 Akebia Therapeutics shares in Q1 2026, an estimated $818K.
  • Akebia Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #1880 holding.
  • Qube Research & Technologies (QRT) first reported a position in Akebia Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Qube Research & Technologies (QRT)'s Akebia Therapeutics position peaked at $8.75M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.